---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-007705"
form_type: "8-K"
ticker: "OSTX"
cik: "0001795091"
company_name: "OS Therapies Inc"
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:12:45.417848+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OS Therapies acquires Ayala's listeria IP for $8M, eliminates milestones, adds Phase 2 lung asset

## Summary
- Total consideration $8M: $0.5M cash + $7.5M in OSTX shares; 180-day lock-up. Closes ~60 days.
- Eliminates $3.5M BLA milestone and $16.5M in OST-HER2 sales milestones; royalty reduced from 10% to 1.5% under Penn License.
- Adds Phase 2 ADXS-503 (NSCLC) and Phase 1 ADXS-504 (prostate) programs using Listeria monocytogenes platform.
- Karim Galzahr appointed to board; managing partner at OKG Capital, over 30 yrs finance experience.
- Company has $7.1M financing at $4/share; cash runway into 2026; no equity raises below $12 for 6 months.

## SEC filing metadata
- accession: 0001213900-25-007705
- form_type: 8-K
- ticker: OSTX
- cik: 0001795091
- company_name: OS Therapies Inc
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/0001213900-25-007705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/ea0229055-8k_osthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-007705
- JSON: https://secwatch.observer/filing/0001213900-25-007705.json
- Plain text: https://secwatch.observer/filing/0001213900-25-007705.txt

## Key facts
- Executive change
  Karim Galzahr was elected as Director at OS Therapies Inc.
  - Action: elected
  - Role: Director
  source text: On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1795091/000121390025007705/0001213900-25-007705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.